ArticleIranian journal of reproductive medicine2015
Association of follicle stimulating hormone receptor promoter with ovarian response in IVF-ET patients.
Article in Iranian journal of reproductive medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Exploring genotype-phenotype correlation of FSHR polymorphisms in polycystic ovary syndrome.BMC endocrine disorders · 2025Article
- An update review of the application of single-cell RNA sequencing in pregnancy-related diseases.Frontiers in endocrinology · 2024Review
- Single-cell RNA-seq analysis and cell-cluster deconvolution of the human preovulatory follicular fluid cells provide insights into the pathophysiology of ovarian hyporesponse.Frontiers in endocrinology · 2022Article
- Predictive Factors for Live Birth in FreshFrontiers in endocrinology · 2021Article
- Identification of chicken FSHR gene promoter and the correlations between polymorphisms and egg production in Chinese native hens.Reproduction in domestic animals = Zuchthygiene · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor ovarian response phenomenon has been observed in some of the in vitro fertilization-embryo transfer patients. Some investigations found that follicle stimulating hormone receptor ( FSHR ) gene plays a role in the process, but no direct evidence shows the correlation between genotypes of FSHR and ovarian response.
objectiveExploring the molecular mechanism behind the mutation of FSH R promoter association with ovarian granulosa cells and poor ovarian response. MATERIALS AND
methodsThis cross sectional study was performed using 158 women undergoing the controlled short program ovarian stimulation for IVF treatment. The 263 bp DNA fragments before the follicle stimulating hormone (FSH) receptor 5' initiation site were sequenced in the patients under IVF cycle, 70 of which had poor ovarian response and 88 showed normal ovarian responses.
resultsWith a mutation rate of 40%, 63 in 158 cases showed a 29(th) site G→A point mutation; among the mutated cases, the mutation rate of the poor ovarian responders was significantly higher than the normal group (60% versus 23.9%; χ2=21.450, p<0.001). Besides, the variability was also obvious in antral follicle count, and ovum pick-ups. The estradiol peak values and the number of mature eggs between the two groups had significant difference. However, there was no obvious variability (t=0.457, p=0.324) in the basic FSH values between the two groups (normal group, 7.2±2.3 U/L; mutation group, 7.1±2.0 U/L).
conclusionThe activity of FSHR promoter is significantly affected by the 29(th) site G→A mutation that will weaken promoter activity and result in poor response to FSH.
Indexed as
Identifiers
26730247PMC4695687W2341012287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.